Source comparison
IGF-1 LR3 Dosage Fat Loss 2026: Comparison Table
20mcg daily Fasted state (10+ hours), pre-workout 4–8 weeks 0.8–1.2 kg fat mass reduction Minimal; occasional transient hypoglycemia (<5% subjects) Effective threshold dose for measurable substrate shift; lower risk profile but slower kinetics 40mcg daily Fast
This comparison does not assign a generated winner or score.
- 20mcg daily
- Fasted state (10+ hours), pre-workout
- 4–8 weeks
- 0.8–1.2 kg fat mass reduction
- Minimal; occasional transient hypoglycemia (<5% subjects)
- Effective threshold dose for measurable substrate shift; lower risk profile but slower kinetics
- 40mcg daily
- Fasted state, 60–90 min carb restriction post-dose
- 6–12 weeks
- 1.8–2.5 kg fat mass reduction
- Hypoglycemia (8–12% subjects), mild joint discomfort (5%)
- Optimal balance of efficacy and tolerability in most published protocols; most consistent fat oxidation data
- 60mcg daily
- Fasted state, 90 min carb restriction post-dose
- 8–12 weeks
- 2.2–3.1 kg fat mass reduction
- Hypoglycemia (15–20%), joint effusion (8–10%), receptor desensitization risk at >12 weeks
- Upper range before diminishing returns; requires glucose monitoring and structured dietary timing
- 80–100mcg daily
- Fasted state, strict carb timing
- 4–8 weeks (short cycles only)
- 2.5–3.4 kg fat mass reduction
- Hypoglycemia (20–25%), edema (12–15%), nausea, potential receptor downregulation
- Rarely used in human research beyond 8 weeks; adverse event rate exceeds incremental fat loss benefit
- Post-meal dosing (any dose)
- Within 2 hours of carbohydrate intake
- Any duration
- Negligible to zero fat loss vs placebo
- Same dose-dependent risks without metabolic benefit
- Timing failure negates lipolytic mechanism entirely; insulin interference documented across all dose ranges